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 Introduction: Iron deficiency (ID) is an emerging problem in patients with chronic 
systolic heart failure and can be a potential therapeutic target. However, not much is known 
about the frequency, predictors of iron deficiency and anemia in patients with chronic heart 
failure. 
 
 Objectives:  The primary objective of this study was to determine the frequency of iron 
deficiency in chronic systolic heart failure patients who were follow up in Hospital Universiti 
Sains Malaysia. The secondary objectives included were to determine the frequency of anemia in 
the same study population, correlation between ejection fraction and blood parameters and 
determining risk factors for anemia in chronic systolic heart failure.   
 
 
 Methods: A total of 81 patients who were followed up in Hospital Universiti Sains 
Malaysia were recruited into this cross sectional study using purposive sampling method. These 
patients had history of chronic systolic heart failure for more than 6 months with left ventricular 
ejection fraction less than 45% as assessed by echocardiography using Simpson’s planimetric 
method. 10mls of venous blood was drawn from each participant and analyzed. 
 
 Result: Thirty three patients were anemic (40.7%) as compared to 48 patients (59.3%) 
who did not. Sixteen patients were iron deficient (19.8%). All iron deficiency patients were 
anemic patients. There were positive correlation between serum ferritin (r=0.624, p<0.001), 
transferrin saturation (r= 0.346, p<0.001) and hemoglobin (r=0.528, p<0.001) with ejection 
fraction, respectively. Anemia in chronic systolic heart failure was independently associated with 
serum ferritin  (OR 0.974, 95% CI 0.959, 0.988), transferrin saturation (OR 0.831, 95% CI 
0.726, 0.952), and diabetes mellitus (OR 6.680, 95% CI 1.599, 27.897) based on multiple logistic 
regression analysis. 
 
 Conclusion: This study demonstrated high frequency of anemia in chronic systolic heart 
failure patients. Majority of anemic patients were iron deficient. Besides that, serum hemoglobin 
and serum ferritin and transferrin saturation were positively correlated with left ventricular 
ejection fraction. It is recommended in future, an appropriately powered randomized trials with 
correction of anemia using erythropoietin and intravenous iron be carried out to validate the 
study findings. 
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ABSTRAK 
 
Latar belakang:  Kekurangan zat besi adalah masalah baru yang dikaitkan dengan penyakit 
kegagalan jantung kronik dan ia berpotensi sebagai sasaran perawatan. Malah, pengetahuan 
mengenai kekerapan kes kekurangan zat besi dan kekurangan sel darah merah di kalangan 
pesakit kegagalan jantung kronik masih kurang. 
 
Objektif : Objektif pertama kajian ini adalah untuk  mengenalpasti kekerapan kes kekurangan zat 
besi dikalangan pesakit kegagalan jantung kronik. Objektif sekunder adalah untuk menentukan 
kekerapan kes kekurangan sel darah merah pada populasi yang sama. Hubungan antara kekuatan 
sistolik jantung dan keputusan darah juga dikenalpasti. Pada masa yang sama, faktor risiko untuk 
menghidap kekurangan sel darah merah di dalam kes kegagalan jantung kronik juga dianalisa. 
 
Kaedah: Satu kajian keratan rentas yang melibatkan sejumlah 81 orang pesakit dari Hospital 
Universiti Sains Malaysia yang menghidap penyakit kegagalan jantung kronik telah terlibat 
dalam kajian ini. Pesakit-pesakit tersebut mempunyai kekuatan sistolik jantung kurang dari 45% 
mengikuti ukuran Simpson dan disah menghidapi kegagalan jantung melebihi 6 bulan. Sebanyak 
10 mls darah diambil daripada setiap pesakit and dihantar ke makmal untuk analisa. 
 
Keputusan : Enam belas orang pesakit didapati mengalami kekurangan zat besi (19.8%). Tiga 
puluh tiga pesakit disahkan mengalami kekurangan sel darah merah (40.7%) berbanding dengan 
48 pesakit (59.3%) yang normal kandungan sel darah merah.  
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Semua pesakit kekurangan zat besi adalah dari golongan kekurangan darah merah. Terdapat 
hubungan positif antara kandungan ferritin, zat besi dan sel darah merah dengan kekuatan 
sistolik jantung. Kandungan ferritin (OR 0.974, 95% CI 0.959, 0.988), ketepuan transferrin     
(OR 0.831, 95% CI 0.726, 0.952), dan penyakit kencing manis (OR 6.680, 95% CI              
1.599, 27.897) merupakan risiko untuk menhidapi penyakit kekurangan darah merah. 
 
Kesimpulan : Kajian ini menunjukan bahawa kes kekurangan sel darah merah dalam kes 
kegagalan jantung kronik mempunyai kekerapan yang tinggi. Kebanyakan pesakit kekurangan 
sel darah merah terdiri daripada pesakit yang kekurangan zat besi. Selain daripada itu, 
kandungan hemoglobin, ferritin dan ketepuan transferrin berkait dengan kekuatan sistolik 
jantung. Pada masa depan, disarankan kajian mengenai rawatan kekurangan sel darah merah 
dengan ubat erythropoietin dan pengambilan zat besi perlu dijalankan untuk mengesah keputusan 
kajian ini. 
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ABSTRACT 
 
Background:  Iron deficiency (ID) is an emerging problem in patients with chronic systolic heart 
failure and can be a potential therapeutic target. However, not much is known about the 
frequency, predictors of iron deficiency and anemia in patients with chronic heart failure. 
 
Objectives:   The primary objective of this study was to determine the frequency of iron 
deficiency in chronic systolic heart failure patients who were follow up in Hospital Universiti 
Sains Malaysia. The secondary objectives included were to determine the frequency of anemia in 
the same study population, correlation between ejection fraction and blood parameters and 
determining risk factors for anemia in chronic systolic heart failure.   
 
Methods:   A total of 81 patients who were followed up in Hospital Universiti Sains Malaysia 
were recruited into this cross sectional study using purposive sampling method. These patients 
had history of chronic systolic heart failure for more than 6 months with left ventricular ejection 
fraction less than 45% as assessed by echocardiography using Simpson’s planimetric method. 
10mls of venous blood was drawn from each participant and analyzed. 
 
Results:  Thirty three patients were anemic (40.7%) as compared to 48 patients (59.3%) who did 
not. Sixteen patients were iron deficient (19.8%). All iron deficiency patients were anemic 
patients. There were positive correlation between serum ferritin (r=0.624, p<0.001), transferrin 
saturation (r= 0.346, p<0.001) and hemoglobin (r=0.528, p<0.001) with ejection fraction, 
respectively.  
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Anemia in chronic systolic heart failure was independently associated with serum ferritin        
(OR 0.974, 95% CI 0.959, 0.988), transferrin saturation (OR 0.831, 95% CI 0.726, 0.952), and 
diabetes mellitus (OR 6.680, 95% CI 1.599, 27.897) based on multiple logistic regression 
analysis. 
 
Conclusion: This study demonstrated high frequency of anemia in chronic systolic heart failure 
patients. Majority of anemic patients were iron deficient. Besides that, serum hemoglobin and 
serum ferritin and transferrin saturation were positively correlated with left ventricular ejection 
fraction. It is recommended in future, an appropriately powered randomized trials with correction 
of anemia using erythropoietin and intravenous iron be carried out to validate the study findings. 
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CHAPTER 1 
INTRODUCTION 
1.1    Chronic systolic heart failure; epidemiologic perspective 
Heart failure (HF) is the end stage of most diseases of the heart. The prevalence of HF varies 
between 3-20 per 1000 population, but for those over the age of 65 years, it could be as high as 
100 per 1000 population (Davis et al., 2000). 
The prognosis for HF is poor, far worse than some of the common cancer (Kannel et al., 1982). 
The one year mortality rate varies between 5% to 52% depending on the severity and the 
presence of co-morbidity (Investigators, 1992). In a large community based study, about 40% of 
individuals with HF died within a year of initial diagnosis (Cowie et al., 2000). About half of all 
deaths are sudden and may occur at any stage of the syndrome (Cleland et al., 2001). Heart 
failure is an important cause of hospitalization accounting for about 10% of all medical 
admissions in Malaysia (Teh BT, 1999). About 45% of patients with HF are readmitted at least 
once within 12 months for acute decompensation (Krumholz et al., 1998). More recent 
epidemiological studies from the West seem to indicate that the prognosis has improved slightly 
with earlier detection of the condition and improved treatment strategies (MacIntyre et al., 2000; 
Schaufelberger et al., 2004). 
Heart failure is a clinical syndrome characterized by symptoms of breathlessness and fatigue, 
with signs of fluid retention and supported by objective evidence of cardiac dysfunction (systolic 
and/or diastolic). The severity of the symptoms may be graded according to the New York Heart 
Association (NYHA) Functional Class. These symptoms may fluctuate in severity with time and 
may completely disappear following therapy. 
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Heart failure is due to the inability of the heart to pump blood at a rate to meet the needs of 
various organs of the body or its ability to do so only at high filling pressures. It may be the 
result of any disorder of the endocardium, myocardium, pericardium or great vessels although 
commonly  it is due to myocardial dysfunction. Myocardial contractility is most often reduced 
resulting in Left Ventricular (LV) systolic dysfunction. 
In LV systolic dysfunction, cardiac output is reduced due to depressed myocardial contractility. 
This initiates a complex pathophysiological process which includes hemodynamic alterations and 
structural changes within the myocardium and vasculature. Activation of neuro-hormones such 
as catecholamine and the renin-angiotension-aldosterone system play a pivotal role in this 
process. 
 
1.2 Definition of chronic systolic heart failure 
Heart failure can be defined as an abnormality of cardiac structure or function leading to failure 
of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing 
tissues, despite normal filling pressures (Dickstein et al., 2008). HF is defined clinically as a 
syndrome in which patients have typical symptoms (e.g. breathless, ankle swelling and fatigue) 
and signs (e.g., elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) 
resulting from an abnormality of cardiac structure or function. Demonstration of an underlying 
cardiac cause is therefore central to the diagnosis of HF. This is usually myocardial disease 
causing systolic ventricular dysfunction. 
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The main terminology used to describe HF is historical and is based on measurement of LV 
ejection fraction (EF). Mathematically, EF is the stroke volume (which is the end-diastolic 
volume minus the end-systolic volume) divided by the end-diastolic volume. In patients with 
reduced contraction and emptying of the left ventricle, stroke volume is maintained by an 
increase in end-diastolic volume. The more severe the systolic dysfunction, the more the EF is 
reduced from normal and generally the greater the end-diastolic and end-systolic volumes. The 
EF is considered important in HF, not only because of its prognostic importance, but also 
because most clinical trials selected patients based upon EF. The major trials in patients with HF 
and a reduced EF or systolic HF mainly enrolled patients with an EF < 45%, and it is only in 
these patients that effective therapies have been demonstrated to date (Guidelines, 2012). 
 
A patient who has never exhibited the typical signs or symptoms of HF is described as having 
asymptomatic LV systolic dysfunction. Patients who have had HF for some time are often said to 
have ‘chronic HF’. A treated patient with symptoms and signs, which have remained generally 
unchanged for at least a month, is said to be ‘stable’. If chronic stable HF deteriorates, the patient 
may be described as ‘decompensated’ and this may happen suddenly ‘acute’, leading to hospital 
admission  (Dunlay et al., 2009; McMurray et al., 2010; Chen et al., 2011). Symptoms can also 
change rapidly and an acutely unwell patient with pulmonary edema with NYHA class IV 
symptoms may improve rapidly with administration of a diuretic. Deterioration in symptoms 
indicates heightened risk of hospitalization and death and is an indication to seek prompt medical 
attention and treatment.  
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1.3  New York Heart Association functional classification 
The NYHA functional classification has been used to select patient in almost all randomized 
treatment trials in HF. Patients in NYHA class I have no symptoms attributable to heart disease, 
those in NYHA classes II, III or IV are said to have mild, moderate or severe symptoms 
respectively.  
 
1.4 Role of echocardiography in the evaluation of heart failure 
Imaging plays a central role in the diagnosis of HF and in guiding treatment. Among the several 
imaging modalities available, echocardiography is the method of choice in patients with 
suspected HF for reasons of accuracy, availability, safety and cost. 
Echocardiography is a term used to refer to all cardiac ultrasound imaging techniques, including 
two-dimensional/ three-dimensional echocardiography, pulsed and continuous wave Doppler, 
color flow Doppler and tissue Doppler imaging. Echocardiography provides information about 
cardiac anatomy and function.  
Left ventricular ejection fraction (LVEF) is not the same as stroke volume. Stroke volume may 
be maintained by LV dilation in patient with reduce EF. The recommended echocardiographic 
method for measurement of EF is the apical biplane method of discs (the modified Simpson’s 
rule). The Teichholz methods of calculating EF from linear dimensions may result in 
inaccuracies, particularly in patients with regional LV dysfunction (Kirkpatrick et al., 2007; 
Rudski et al., 2010; Dokainish et al., 2011). 
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1.5 Management of chronic systolic heart failure 
Drug therapy is the mainstay of management of chronic systolic heart failure. The most effective 
therapy is combination of diuretic, angiotension-converting enzyme inhibitor, beta-blocker and 
aldosterone receptor antagonist. 
a) Angiotensin-Converting Enzyme Inhibitors (ACEI) 
ACEI improve survival and quality of life in all classes of heart failure  (SOLVD, 1992). ACEI 
are first-line drugs for the treatment of HF and should be given to all patients in whom there is 
evidence of left ventricular (LV) systolic dysfunction as reflected by an LV ejection fraction     
of < 45%.  
b) Angiotensin II Receptor Blockers (ARB) 
ARB should be considered in patients intolerant to ACEI. In post myocardial infarction (MI) 
patients with impaired LV function, the ARB Valsartan was found to be as effective as captopril 
(Cohn and Tognoni, 2001). In patients with severe HF, the combination of ACEI and ARB may 
be considered to reduce hospitalization due to HF (Granger et al., 2003). 
c) Beta-Blockers 
Large clinical trials have shown that beta-blockers reduce morbidity and mortality in heart 
failure patients with NYHA II-IV, regardless of ischemic or non-ischemic aetilogy. Beta-
blockers therapy should be initiated when pulmonary congestion is absent and the patients is 
clinically stable. All stable patients with current or prior symptoms of HF and reduced LV 
ejection fraction should be given β-blockers unless contraindicated (Merit-HF, 1999; Poole-
Wilson et al., 2003; Doughty et al., 2004). 
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A recent trial indicated that initiating therapy with beta-blockers first is non-inferior to the 
standard approach of starting with an ACEI. The benefits seen with both these drugs are additive 
(Poole-Wilson et al., 2003). 
Patients who decompensate and are admitted in acute heart failure may need reduction or 
temporary discontinuation of their beta-blockers. After the patient has been stabilized and is no 
longer in overt HF, an attempts should be made to reinstitute beta-blockers starting with low 
doses. 
 
d) Aldosterone Receptor Antagonists 
The addition of spironolactone to ACEI, loop diuretics and digoxin in patients with severe HF 
reduces mortality and hospitalization (Pitt et al., 1999). Another aldosterone receptor antagonist,  
eplerenone when added to beta-blockers and ACEI has been shown to be beneficial when given 
to post MI patients with impaired LV function and mild HF (Pitt et al., 2003). 
Care should be exercised in patients with renal impairment. Serum potassium should be 
monitored regularly. Potassium supplements may need to be reduced or stopped.  
e) Digoxin 
Digoxin is indicated in patients with HF and atrial fibrillation (Cleland et al., 2002). 
Combination of digoxin and beta-blockers is superior to either agent alone in patients with atrial 
fibrillation (Khand et al., 2003). 
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In patients with HF and normal sinus rhythm, digoxin may be added if symptoms persist despite 
diuretics, ACEI, beta-blockers and low dose spironolactone. Digoxin has no effect on mortality 
but reduces hospitalization (Uretsky et al., 1993; Digitalis, 1997). 
f) Antiplatelet agents 
Antiplatelet therapy consists of acetylsalicyclic acid (ASA), an cyclo-oxygenase inhibitor and 
clopidogrel and ticlopidine, both adenosine diphosphate receptor (ADP) antagonists. Antiplatelet 
is the main treatment regime for ischemic heart disease, which is the main etiology for systolic 
heart failure. 
ASA acts by inhibiting cyclooxygenase-1 with platelets, hence preventing the formation of 
thromboxane A2 which inhibits platelet aggregation. Additionally, ASA may also reduce plague 
rupture and its sequalae (Ridker et al., 1997). Antiplatelet Trialists Collaboraton 1994, a 
collaborative overview of randomized trials of antiplatelet therapy noted significant reduction of 
death, myocardial infarction and stroke in various categories of patients by 25% (Collaboration, 
1994).  
ADP antagonists blocks adenosine diphosphate receptor resulting in inhibition of platelet 
aggregation. CAPRIE steering committee 1996, reported relative risk reduction in incidence of 
ischemia, myocardial infarction (MI) or vascular death by 8.7% in favor of clopidogrel when 
patients were randomized to receive either ASA 325mg/day or clopidogrel 75mg/day (Gent et 
al., 1996). CURE trial showed significant reduction in incidence of cardiovascular death, 
nonfatal MI or stroke by 9.3% in patients who were given clopidogrel (300mg immediately 
followed by 75mg/day) within 24 hours after onset of acute coronary syndrome (ACS)       
(Yusuf et al., 2001). 
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g) Diuretics 
Diuretics are indicated in all patients with HF in whom there are signs and symptoms of fluid 
retention (Hampton, 1994). The dose of diuretic used is wide and dependent on individual 
requirements. Diuretic therapy must be used with care because overdiuresis can cause severe 
intravascular dehydration and deteriorating renal function. Thiazide diuretics may be preferred in 
patients with hypertensive HF and mild fluid retention. For most patients, a loop diuretic is often 
required. Responsiveness to loop diuretics diminished as HF progresses. In this situation, 
combination of thiazides and loop diuretics are useful as these drugs work synergistically to 
improve diuresis  (Dormans et al., 1998).  
 
1.6 Risk factors and co-morbidities associated with chronic systolic heart failure 
Co-morbidities are important in patients with HF for four main reasons. First, co-morbidities 
may affect the use of treatments for HF. Secondly, the drugs used to treat co-morbidities may 
cause worsening of HF. Thirdly, the drugs used to treat HF and those used to treat co-morbidities 
may also interact with one another and reduce patient adherence. Lastly, most co-morbidities are 
associated with worse clinical status and are predictors of poor prognosis in HF. This has led to 
some co-morbidities themselves becoming targets for treatment (McMurray et al., 2009). 
a) Anemia 
Anemia (defined as hemoglobin concentration <13g/dL in men and <12g/dL in women) is 
common in HF, particularly in hospitalized patients. It is more frequent in women, the elderly 
and in patients with renal impairment (Felker et al., 2003).  
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Anemia is associated with more symptoms, worse functional status, greater risk of HF 
hospitalization and reduce survival. A standard diagnostic work-up should be undertaken in 
anemia patients. Although no definite etiology is identified in many patients, correctable causes 
should be treated in the usual way. Correction of iron deficiency using intravenous iron has been 
specifically studied in patients with HF. The value of erythropoietin-stimulating agents as a 
treatment for anemia of unknown etiology  is unknown but is currently being tested in a large 
mortality-morbidity randomized control trial (RCT) (McMurray et al., 2009).  
 
b) Diabetes mellitus 
Hyperglycemia and diabetes mellitus are very common in HF and diabetes mellitus is associated 
with poorer functional status and worse prognosis (Bauters et al., 2003). Diabetes may be 
prevented by treatment with ARBs and possibly ACE inhibitors (McMurray et al., 2010). Beta-
blockers are not contraindicated in diabetes and are as effective in improving outcome in diabetic 
patients as well as in non-diabetic individuals (Jonas et al., 1996). Different beta-blockers may 
have different effects on glycemic indices (Bakris et al., 2005). Thiazolidinediones cause sodium 
and water retention and increased risk of worsening HF and hospitalization and should be 
avoided. Metformin is not recommended in patients with severe renal or hepatic impairment 
because of the risk of lactic acidosis but is widely used in other patients with HF          
(MacDonald et al., 2010). The safety of newer antidiabetic drugs in HF is unknown.  
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c) Hyperlipidemia 
Elevated low-density lipoprotein cholesterol is uncommon in HF, Patients with advanced HF 
often have low concentrations of low-density lipoprotein, which is associated with a worse 
prognosis (Horwich et al., 2002). Rosuvastatin did not reduce the primary composite mortality-
morbidity endpoint in two large RCTs in heart failure (Tavazzi et al., 2008).  
 
d) Hypertension 
Hypertension is associated with an increased risk of developing HF, antihypertensive therapy 
markedly reduces the incidence of HF (Furberg et al., 2000). Negatively inotropic calcium 
channel blockers (CCB) should not be used to treat hypertension in patients with HF, and 
moxonidine should also be avoided in patients with HF as it increased mortality in patients in 
one RCT (Cohn et al., 2003). If blood pressure is not controlled with an ACE inhibitor, a beta-
blocker, aldosterone receptor antagonist, diuretic, hydralazine and amlodipine, are additional 
blood pressure-lowering agents shown to be safe in systolic HF. The blood pressure targets 
recommended in hypertension guidelines are applicable to HF (Myat et al., 2012). 
 
e) Iron deficiency 
Iron deficiency may contribute to muscle dysfunction in HF and causes anemia if continually 
depleted. In a single RCT, 459 patients with  systolic HF whose  hemoglobin concentration range 
between 9.5 and 13.5g/dL plus iron deficiency were randomized 2:1 to iv ferric carboxymaltose 
or saline.  
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Over 6 months of treatment, iron therapy improved patients’ functional class compared to 
placebo (Anker et al., 2009b). In that trial, iron deficiency was diagnosed when serum ferritin 
was < 100 μg /L or when the ferritin concentration was between 100 and 299 μg/L and 
transferrin saturation was < 20%. Iron therapy may be considered as a treatment for these 
patients. However the long-term safety of iron therapy in HF is unknown.  
 
f) Kidney dysfunction and cardiorenal syndrome 
The glomerular filtration rate (GFR) is reduced in most patients with HF, and renal function is a 
powerful independent predictor of prognosis in HF. Renin-angiotensin-aldosterone blockers 
frequently cause a fall in GFR. Conversely an immediate and large fall in  GFR should raise the 
suspicion of renal artery stenosis. Sodium and water depletion and hypotension are well 
recognized causes of renal dysfunction. There are also less well known causes for renal 
dysfunction which are volume overload, right heart failure and renal venous congestion. Other 
causes of kidney dysfunction are prostatic obstruction and nephrotoxic drugs such as NSAIDs 
and certain antibiotic. All of these causes should be considered in HF patients with worsening 
renal function. Thiazide diuretics may be less effective in patients with a very low GFR, and 
certain renally excreted drugs may accumulate in patients with renal impairment. Sometimes the 
term ‘cardiorenal syndrome’ is used to describe concurrent heart and renal failure              
(Ronco et al., 2009). 
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g) Obesity 
Obesity is a risk factor for HF and complicated its diagnosis because it cause dyspnea, effort 
intolerance and ankle swelling and may result in poor-quality echocardiography images. Obese 
individuals also have reduced natriuretic peptide levels. Obesity is more common in  HF-
preserve ejection fraction (HF-PEF) than in HF-reduce ejection fraction (HF-REF). Although it 
is possible that misdiagnosis may explain at least some of this difference in prevalence.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Iron deficiency and anemia in chronic systolic heart failure  
Despite improvements in chronic heart failure (HF) treatment over the years, normal daily 
activities of many patients remain restricted . Anemia, a common comorbidity in HF is 
associated with increased disease severity and may contribute to a worse outcome (Groenveld et 
al., 2008; Ghali, 2009; Jankowska et al., 2010; Haehling et al., 2011). The mechanism where 
anemia contributes to adverse outcome in chronic HF patients is complex and multifactorial (van 
der Meer and van Veldhuisen, 2009).  Important factors include renal failure, bone marrow 
resistance to erythropoietin, chronic inflammation, and iron deficiency (ID)  (van der Meer et al., 
2005; Westenbrink et al., 2007; van Veldhuisen et al., 2011). Traditionally, the presence of ID is 
only considered clinically relevant in the presence of anemia. However, a reduced hemoglobin 
levels can be viewed as the end result of a process beginning with gradual depletion of iron 
stores (Semba, 2003). Even if patients are not anemic, ID may already be common in chronic HF 
(Jankowska et al., 2010; Silverberg, 2011).  ID with or without anemia is associated with 
decreased aerobic performance and exercise intolerance (Pinhas-Hamiel et al., 2003). ID recently 
also shown in chronic HF (Klip et al., 2013). 
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In recent years, a number of studies have shown that correction of ID through intravenous iron 
supplementation in patients with chronic HF may improve functional status and quality of life  
(Toblli et al., 2007; Usmanov et al., 2008; Okonko et al., 2011). This was observed in both 
anemic and non-anemic patients with chronic HF, shifting the focus for anemia in HF away from 
hemoglobin and toward iron (Anker et al., 2009b). The prevalence and potential importance of 
ID per se, irrespective of hemoglobin are currently a subject of interest in HF. However, data on 
this topic are scarce and only a few studies have reported on ID as a predictor of outcome in 
chronic HF.  
 
2.2  Prevalence and definition of iron deficiency (ID) 
In recent years, the prevalence and prognosis of ID in chronic HF have received greater 
attention. Despite this, there is no standard definition of ID in chronic HF, leading to a wide 
variation in reported prevalence. 
Opasich et al (2005) reported that among 148 patients with chronic HF and anemia, impaired 
iron supply was the cause in nearly all patients with anemia of chronic disease. In a large 
observational trial by Jankowska et al (2010),  ID was present in 37% of all chronic systolic HF 
patients. In another recent study, Parikh et al (2011) reported a prevalence of 61% among 
community-dwelling HF patients. 
Chronic HF is a cardiovascular syndrome with a high mortality, and iron deficiency has been 
shown to be an independent risk factor for mortality in HF (Pitt et al., 2003).  
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About half of all patients with HF have either absolute iron deficiency (ferritin < 100µg/L and  
TSAT <20%) or functional iron deficiency (serum ferritin 100-300µg/L and TSAT <20%) 
respectively. This finding is only partly associated with the presence of anemia. Indeed, many 
HF patients present with iron deficiency, many with anemia, and some of these with both. Iron 
deficiency independently relates to exercise intolerance expressed as reduced peak oxygen 
uptake and augmented ventilator response to exercise in patients with chronic HF (Okonko et al., 
2008). The absence of iron in the blood of patients with HF may be also reflected as reduced iron 
load in the bone marrow and in the myocardium. At the level of the bone marrow, the dominant 
regulatory protein that controls synthesis of new erythrocytes is erythropoietin. Erythropoietin is 
synthesized predominantly in the peritubular endothelium cells of the kidney (Lacombe et al., 
1988). During anemia, caused by either reduced iron intake or blood loss, the healthy kidney can 
increase erythropoietin production by at least 10-fold. The symptoms and signs of iron 
deficiency are partially explained by the presence of anemia, but experimental evidence suggests 
that iron itself improves muscle function and exercise capacity in animals without changes in 
hemoglobin levels. This finding emphasizes the role of iron as a co-factor in skeletal and cardiac 
muscle function. The reason why iron may have an effect on HF irrespective of anemia and 
hemoglobin values is that iron is an essential constituent of myoglobin, which is found in the 
cytoplasm and avidly binds and releases oxygen. Mitochondrial function needs iron since iron is 
a co-factor for heam proteins that are involved in electron transfer of ATP and energy production 
in the cells (Rouault and Tong, 2005). In recent years, different therapeutic possibilities embrace 
iron replacement by oral or  intravenous routes. 
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Serum iron markers, however, may be inadequate to detect decreased iron status. Only 1 study 
conducted by Nanas et al (2006) used the criterion standard of bone marrow iron staining to 
determine the prevalence of ID in patients with chronic HF. They found that 73% of patients 
with advanced HF and anemia had depleted iron stores. Nonetheless, the criteria most commonly 
used for detecting ID in chronic HF are a ferritin level <100 μg/L or ferritin 100 to 299 μg/L in 
combination with a TSAT <20% (Klip et al., 2013). 
 
2.3  Pathophysiology of ID in chronic HF 
Iron is a metabolically active micronutrient. One of its crucial properties is the ability to shuttle 
between two oxidative states (ferric and ferrous iron), which makes it an efficient cofactor for 
several enzymes and the catalyst of numerous biochemical reactions. Iron plays a crucial role in 
oxygen transport (as a component of hemoglobin), oxygen storage (as a component of 
myoglobin), oxidative metabolism in the skeletal and heart muscle (as a component of oxidative 
enzymes and respiratory chain proteins, and also is involved in the synthesis and degradation of 
lipids, carbohydrates, DNA, and RNA. The maintenance of normal iron metabolism is 
particularly important for cells that are characterized by high mitogenic potential (neoplastic 
cells, hematopoietic cells, including immune competent cells) and high energy demand 
(hepatocytes, adipocytes, renal cells, immune cells, skeletal myocytes, and cardiomyocytes). Iron 
deficiency (ID) is the most common nutritional disorder, affecting more than one-third of the 
general population (Zimmermann and Hurrell, 2007). 
 
21 
 
Iron deficiency has been also recognized to complicate chronic diseases (e.g. inflammatory 
bowel disease, Parkinson's diseases, rheumatoid diseases, and chronic renal failure) with or 
without concomitant anemia (Weiss, 2009). The presence of ID may have multifaceted clinical 
consequences, not only directly related to impaired erythropoiesis but also to marked impairment 
of oxidative metabolism, cellular energetics, and cellular immune mechanisms (Jankowska et al., 
2010).  
It was recently shown that patients with chronic HF are more susceptible to become iron 
deficient. This could be explained by gradual depletion of iron stores due to low iron intake, 
gastrointestinal blood loss, or iron malabsorption.  
Patients with chronic HF are prone to become iron deficient as a consequence of a depletion of 
iron stores (absolute ID) or more frequently as a result of impaired iron metabolism in the course 
of inflammatory processes characterizing chronic HF (functional ID). In chronic HF, there is an 
activation of proinflammatory cytokines that block intestinal absorption of iron and divert iron 
from the circulation into the reticuloendothelial system, causing reticuloendothelial block. 
Hepcidin, a small hepatic peptide secreted in response to proinflammatory cytokines, seems to 
play a key role in the control of these processes. Decreased intestinal iron absorption together 
with its accumulation within the reticuloendothelial stores reduces iron availability to its target 
tissues and organs. Thus, functional ID may occur despite adequate iron stores in the body, in 
contrast to absolute ID, when the body iron stores are significantly depleted.  
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In human, intracellular iron is stored as ferritin and in times of iron overload, as hemosiderin 
whose excessive presence in macrophages is responsible for the color of hematoma. Values of 
serum ferritin are a clinically meaningful proxy to reflect body iron stores as this protein spills 
over  from intracellular stores into the bloodstream. Ferritin is also an acute phase reactant whose 
levels may increase during inflammatory process. Transferrin saturation reflect the relative 
amount of transferrin that is loaded with iron. In contrast to ferritin, transferrin is a negative 
acute phase reactant, its levels decrease during times of inflammation. Neither serum iron nor 
serum transferrin alone should be used as indicators of iron status. Chronic inflammation, 
commonly observed in chronic HF may also play a role. Inflammation causes reduced iron 
absorption and availability of iron recycled in the reticuloendothelial system (functional ID)  
(Weiss and Goodnough, 2005; Weiss, 2009).  Therefore, functional ID may occur despite 
adequate iron stores, whereas iron stores are depleted in absolute ID. 
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CHAPTER 3 
OBJECTIVES 
3.1 Primary Objective 
To determine the frequency of iron deficiency in patients with chronic systolic heart failure. 
 
3.2 Secondary Objectives 
3.2.1    To determine the frequency of anemia in patients who diagnosed chronic systolic heart  
            failure. 
3.2.2    To determine the correlation between left ventricular ejection fraction with selected 
             hematological parameters. 
3.2.3    To determine factors associated with anemia in chronic systolic heart failure. 
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CHAPTER 4    
METHODOLOGY 
3.1         Study design 
This is a cross sectional study of patients who have chronic systolic heart failure in 
Hospital USM.  
3.2         Study approval 
This study was approved by the Research and Ethic Committee, Universiti Sains 
Malaysia on 27th October 2014. Study protocol code  USM/JEPeM/14080293. 
3.3          Study setting and population 
This study was conducted in Hospital Universiti Sains Malaysia (HUSM). Patients 
diagnosed with chronic systolic heart failure were recruited from echocardiography 
room and cardiology clinic. 
3.4           Inclusion criteria 
1.  Patients with chronic systolic heart failure attending outpatient cardiology clinics 
and echocardiography room. 
2. A documented history of chronic heart failure more than 6 months 
3. Left ventricular ejection fraction (LVEF) less than 45% as assessed by 
echocardiography (performed at the time of screening using Simpson’s 
planimetric method to determine LVEF) 
4. Clinical stability and unchanged medications for more than 1 month preceding the 
study. 
 
